SRR8526723
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- ANGIOGENESIS+0.500
- MYC_TARGETS_V2+0.420
- APICAL_JUNCTION+0.370
- GLYCOLYSIS+0.340
- COAGULATION+0.330
- HYPOXIA+0.300
- MYOGENESIS+0.280
- ADIPOGENESIS+0.260
- CHOLESTEROL_HOMEOSTASIS+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.310
- INTERFERON_GAMMA_RESPONSE-0.250
- ALLOGRAFT_REJECTION-0.170
- PI3K_AKT_MTOR_SIGNALING-0.150
- SPERMATOGENESIS-0.130
- HEME_METABOLISM-0.030
- KRAS_SIGNALING_DN-0.020
- BILE_ACID_METABOLISM+0.000
- WNT_BETA_CATENIN_SIGNALING+0.010
- PANCREAS_BETA_CELLS+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475169 | — | — | 0.889 |
| 2 | SRR8943009 | — | — | 0.859 |
| 3 | R111 | — | — | 0.846 |
| 4 | TCGA-68-7756-01A-11R-2125-07 | — | cohortSQ1 | 0.834 |
| 5 | BS_QP6MSKRE | Spinal Cord Ependymoma | — | 0.827 |
| 6 | c119f5ef.864c.434b.b515.57c27c7ae949 | — | cohortA1 | 0.819 |
| 7 | C3L-02130 | — | cohortSQ1 | 0.815 |
| 8 | SRR2771207 | — | — | 0.813 |
| 9 | TCGA-CR-5247-01A-01R-2016-07 | — | — | 0.803 |
| 10 | TCGA-18-3417-01A-01R-1443-07 | — | cohortSQ1 | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |